Anne Friedland, MD
Hospitalist · Baltimore, MDNPI 1295154318
Payments from drug & device makers
What this record shows
3 manufacturers reported payments, led by Paratek Pharmaceuticals, Inc. at 58.3% of the total.
Across 4 payments — averaging $25.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$60
- Astellas Pharma US Inc$30
- Shionogi Inc$13
Across 3 payments — averaging $30,135 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Paratek Pharmaceuticals, Inc.$71K
- Pfizer$19K
What the payments were for
- Food & beverage$6058%
- Education$4342%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 2 | $60 |
| Astellas Pharma US Inc | 1 | $30 |
| Shionogi Inc | 1 | $13 |
How this compares
$104 in reported general payments places this provider in the 65th percentile of 414 hospitalist providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AvycazCeftazidime/Avibactam | 22 | $116,800 |
| Daptomycin | 28 | $31,135 |
| Meropenem | 33 | $8,369 |
| Sodium Chloride0.9 % Sodium Chloride | 33 | $1,095 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Baltimore
- Eric RitterBaltimore$94K
- Francoise MarvelBaltimore$63K
- Anweshan SamantaBaltimore$24K
- Turja ChakrabartiBaltimore$6K
- Ajay HoodaBaltimore$5K
- Manu MysoreBaltimore$4K
- Nilesh PatelBaltimore$3K
- Ravitej KhunkhunBaltimore$3K
- Ericka CampbellBaltimore$3K
- Nebiyu EshetuBaltimore$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.